Quanterix upgraded to Conviction Buy from Buy at Goldman Sachs

Goldman Sachs added Quanterix to the firm’s Conviction List while keeping a Buy rating on the shares with a $34 price target. The company is well positioned to capture share of the emerging Alzheimer’s disease, and other neurological disease, testing ecosystem through its more affordable blood-based biomarker testing approach, the analyst tells investors in a research note.